Mesa Laboratories Future Growth

Future criteria checks 4/6

Mesa Laboratories is forecast to grow earnings and revenue by 134.3% and 5.6% per annum respectively. EPS is expected to grow by 134.5% per annum. Return on equity is forecast to be 27.2% in 3 years.

Key information

134.3%

Earnings growth rate

134.5%

EPS growth rate

Life Sciences earnings growth	26.0%
Revenue growth rate	5.6%
Future return on equity	27.2%
Analyst coverage	Low
Last updated	21 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:MLI - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	263	14	43	53	2
3/31/2026	248	8	41	47	4
3/31/2025	235	10	30	36	4
9/30/2024	228	-246	36	40	N/A
6/30/2024	224	-250	41	45	N/A
3/31/2024	216	-254	42	44	N/A
12/31/2023	213	1	41	44	N/A
9/30/2023	214	-1	36	40	N/A
6/30/2023	219	2	36	41	N/A
3/31/2023	219	1	23	28	N/A
12/31/2022	222	-1	20	25	N/A
9/30/2022	223	-4	28	33	N/A
6/30/2022	200	-2	23	27	N/A
3/31/2022	184	2	35	39	N/A
12/31/2021	163	8	39	43	N/A
9/30/2021	143	5	36	38	N/A
6/30/2021	139	4	42	44	N/A
3/31/2021	134	3	35	37	N/A
12/31/2020	130	-2	31	32	N/A
9/30/2020	128	-2	31	32	N/A
6/30/2020	121	-2	27	29	N/A
3/31/2020	118	2	25	27	N/A
12/31/2019	110	5	27	28	N/A
9/30/2019	105	10	27	28	N/A
6/30/2019	104	8	24	25	N/A
3/31/2019	103	7	29	31	N/A
12/31/2018	104	10	28	30	N/A
9/30/2018	101	-2	27	29	N/A
6/30/2018	99	0	N/A	30	N/A
3/31/2018	96	-3	N/A	26	N/A
12/31/2017	94	-4	N/A	17	N/A
9/30/2017	94	11	N/A	14	N/A
6/30/2017	95	11	N/A	7	N/A
3/31/2017	94	11	N/A	17	N/A
12/31/2016	94	12	N/A	14	N/A
9/30/2016	90	11	N/A	9	N/A
6/30/2016	88	10	N/A	18	N/A
3/31/2016	85	11	N/A	17	N/A
12/31/2015	78	9	N/A	15	N/A
9/30/2015	76	9	N/A	16	N/A
6/30/2015	73	10	N/A	13	N/A
3/31/2015	71	10	N/A	11	N/A
12/31/2014	68	11	N/A	9	N/A
9/30/2014	64	10	N/A	11	N/A
6/30/2014	58	9	N/A	10	N/A
3/31/2014	53	9	N/A	12	N/A
12/31/2013	50	8	N/A	12	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MLI is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: MLI is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MLI is expected to become profitable in the next 3 years.

Revenue vs Market: MLI's revenue (5.6% per year) is forecast to grow slower than the German market (5.7% per year).

High Growth Revenue: MLI's revenue (5.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MLI's Return on Equity is forecast to be high in 3 years time (27.2%)

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 09:31
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Mesa Laboratories, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Vijay Kumar	Evercore ISI
Paul Knight	Janney Montgomery Scott LLC
Tycho Peterson	Jefferies LLC

Mesa Laboratories Future Growth

Future criteria checks 4/6

Key information

Recent future growth updates

Recent updates

Second quarter 2025 earnings released: EPS: US$0.63 (vs US$0.23 loss in 2Q 2024)

CEO, President & Director recently sold €529k worth of stock

First quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024

Fourth quarter dividend of US$0.16 announced

Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Mesa Laboratories, Inc. announced delayed annual 10-K filing

Full year 2024 earnings released: US$47.21 loss per share (vs US$0.17 profit in FY 2023)

Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024

New minor risk - Share price stability

Upcoming dividend of US$0.16 per share

Third quarter dividend of US$0.16 announced

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024

New minor risk - Share price stability

Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024

Upcoming dividend of US$0.16 per share

Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.084 in 3Q 2023)

Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of Directors

Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024

Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024

Upcoming dividend of US$0.16 per share at 0.7% yield

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.24 profit in 2Q 2023)

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023

Upcoming dividend of US$0.16 per share at 0.5% yield

First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.27 loss in 1Q 2023)

New minor risk - Shareholder dilution

Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023

Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023

Full year 2023 earnings released: EPS: US$0.17 (vs US$0.36 in FY 2022)

Now 24% undervalued after recent price drop

Upcoming dividend of US$0.16 per share at 0.4% yield

Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-Election

Upcoming dividend of US$0.16 per share at 0.4% yield

Third quarter 2023 earnings released: EPS: US$0.084 (vs US$0.39 loss in 3Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023

Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023

Now 21% undervalued after recent price drop

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.

Mesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit Committee

Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Upcoming dividend of US$0.16 per share

Independent Director recently sold €196k worth of stock

Independent Director recently bought €98k worth of stock

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.39 profit in 1Q 2022)

Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022

Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2022

Mesa Laboratories, Inc. Appoints Tony Tripeny to Its Board of Directors

CEO, President & Director recently sold €313k worth of stock

Full year 2022 earnings released

Upcoming dividend of US$0.16 per share

Mesa Laboratories, Inc. Announces Termination of Greg DiNoia as Senior Vice President of Commercial Operations, Effective June 30, 2022

Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2022

Upcoming dividend of US$0.16 per share

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Upcoming dividend of US$0.16 per share

Insider recently sold €78k worth of stock

Second quarter 2022 earnings released: EPS US$0.71 (vs US$0.52 in 2Q 2021)

Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million.

Independent Director recently sold €137k worth of stock

Upcoming dividend of US$0.16 per share

Insider recently sold €152k worth of stock

Mesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell Small Cap Comp Growth Index

CEO, President & Director recently sold €1.4m worth of stock

CEO, President & Director recently sold €292k worth of stock

Full year 2021 earnings released: EPS US$0.66 (vs US$0.32 in FY 2020)

Upcoming dividend of US$0.16 per share

New 90-day low: €216